Orasis Pharmaceuticals ⚠ Under review

About

Headcount over time

Offices

Q&A

What is Orasis Pharmaceuticals' primary product?

Orasis Pharmaceuticals has developed Qlosi™ (pilocarpine HCL ophthalmic solution) 0.4%, a corrective eye drop for the treatment of presbyopia, or age-related blurry near vision, in adults.

When was Orasis Pharmaceuticals founded?

Orasis Pharmaceuticals was founded in September 2015.

What was the most recent funding round for Orasis Pharmaceuticals?

In October 2024, Orasis Pharmaceuticals completed a D Round funding of $68,000,000. Lead investors included Arboretum Ventures and Johnson & Johnson Innovation – JJDC, Inc.

What is the total amount of funding Orasis Pharmaceuticals has raised to date?

Orasis Pharmaceuticals has raised a total of $131,000,000 in funding.

Has Orasis Pharmaceuticals' primary product received FDA approval?

Yes, in October 2023, Orasis Pharmaceuticals announced FDA approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia.

In what countries does Orasis Pharmaceuticals have offices?

Orasis Pharmaceuticals has offices in Israel and the United States.

What is the employee count for Orasis Pharmaceuticals?

Orasis Pharmaceuticals has 51-200 employees.

Did Orasis Pharmaceuticals secure a licensing agreement for Qlosi in Korea?

Yes, in October 2024, Orasis announced a licensing agreement with Optus Pharmaceuticals for the commercialization of Qlosi eye drops in Korea.

Team · 10

Elad Kedar

Founder · Chief Executive Officer

Paul Smith

President and Chief Operating Officer

Julie Speed

Senior Vice President, Head of Strategy and Marketing

Jeff Francis

VP, Sales

Ron Neumann

Chief Medical Officer

Tes Ignacio

VP, Medical Affairs

Yaron Shimon

VP, Finance

Sharon Amzel-Sasson

VP, Pharmaceutical Development and Manufacturing

Iris Meisner

Head of Regulatory Affairs

Sam Fakhoury

VP, Quality and Operations

Sectors & technology

Highlights

Tags